Carfilzomib weekly 20/56mg/m², lenalidomide and dexamethasone for early relapsed refractory multiple myeloma

Authors :: Frank Bridoux
Valentine Richez
Isabelle Princet
Vincent Javaugue
Antoine Brigaud
Delphine Bauwens
Antoine Machet
Hervé Avet-Loiseau
Emmanuel Fleck
Geraldine Durand
Celine Dieval
Niels Moya
Cécile Gruchet
Stéphanie Guidez
Xavier Leleu
Isabelle Azais
Anthony Levy
Arthur Bobin
Guillemette Fouquet
Florence Sabirou
Source :: Journal of Clinical Oncology. 36:8017-8017
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: 8017Background: Triplet-based lenalidomide plus dexamethasone (Rd) combinations have become the new standard of care for early relapse and refractory multiple myeloma (RRMM), including carfilzomib ...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Standard of care
business.industry
Early Relapse
Refractory Multiple Myeloma
medicine.disease
Carfilzomib
chemistry.chemical_compound
chemistry
Internal medicine
Relapsed refractory
medicine
business
Dexamethasone
Multiple myeloma
Lenalidomide
medicine.drug

Full Text Access

Tools